A. Boral

发表

Ceritinib in ALK-rearranged non-small-cell lung cancer.

J. Engelman, Michael Thomas, A. Shaw, 2014, The New England journal of medicine.

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Hartmut Goldschmidt, Mario Boccadoro, David Irwin, 2005, The New England journal of medicine.

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

Anthony Boral, Paul Richardson, Yongsheng Huang, 2006, Blood.

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

J. Leonard, S. de Vos, R. Fisher, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of carboplatin (Car) and docetaxel (Doc) followed by weekly Car/Doc with concurrent radiotherapy (CT/RT) in patients (pts) with stage III non-small cell lung cancer (NSCLC)

D. Sugarbaker, R. Herbst, N. Choi, 2000 .

Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF©

A. Shields, A. Boral, B. Mar, 2021, Orphanet Journal of Rare Diseases.

Phase 2 Study of Bortezomib Weekly or Twice Weekly Plus Rituximab in Patients with Follicular (FL) or Marginal Zone (MZL) Lymphoma: Final Results.

C. Flowers, S. Dakhil, P. Mclaughlin, 2006 .

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

T. Lister, J. Radford, S. Joel, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of class I H-2 antigens in cells transformed by radiation leukemia virus is associated with methylation and rearrangement of H-2 DNA.

J. Buxbaum, A. Boral, R. Kornreich, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

R. Neuwirth, D. Esseltine, H. Goldschmidt, 2008, Leukemia.

Drug‐induced cutaneous vasculitis in patients with non‐Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?

D. Esseltine, J. Teruya-Feldstein, M. Gonen, 2006, British journal of haematology.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma.

A. Shaw, B. Solomon, Dong-Wan Kim, 2015, Blood.

Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element

J. Lenz, A. Boral, S. Okenquist, 1989, Journal of virology.

1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a First-In-Human Phase I Study of the Alk Inhibitor LDK378 in Advanced Solid Tumors

A. Shaw, E. Felip, A. Santoro, 2012 .

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

D. Esseltine, P. Sonneveld, P. Richardson, 2008, British journal of haematology.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

J. Leonard, S. de Vos, R. Fisher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hematologic Profiles in the Phase 3 APEX Trial.

H. Goldschmidt, P. Sonneveld, S. Lonial, 2005 .

Clinical evaluation of biologically targeted drugs: Obstacles and opportunities

S. Dessain, A. Boral, B. Chabner, 2009, Cancer Chemotherapy and Pharmacology.

Relative importance of elements within the SL3-3 virus enhancer for T-cell specificity

J. Lenz, A. Boral, J. E. Losardo, 1990, Journal of virology.

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974

W. Sellers, P. Schultz, Jennifer L. Harris, 2013, Proceedings of the National Academy of Sciences.

Bortezomib-induced tumor lysis syndrome in multiple myeloma.

D. Esseltine, S. Singhal, J. Mehta, 2006, Clinical lymphoma & myeloma.

Translational research: walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lecture.

A. Boral, B. Chabner, P. Multani, 1998, Cancer research.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

D. Esseltine, H. Goldschmidt, P. Wen, 2009, British journal of haematology.

Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS 5132 in Combination with Carboplatin and Paclitaxel in Patients with Previously Untreated, Advanced Non-small Cell Lung Cancer

P. Fidias, T. Lynch, G. Shapiro, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.

P. Fidias, T. Lynch, G. Shapiro, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer 1

P. Fidias, T. Lynch, G. Shapiro, 2001 .

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Anthony Boral, Hartmut Goldschmidt, Mario Boccadoro, 2007, Blood.

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

C. Flowers, S. de Vos, L. Hart, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD).

T. Lister, J. Stec, S. Joel, 2004 .

Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial

G. Mulligan, R. Fisher, M. Fleming, 2010, Leukemia & lymphoma.

Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): A Phase 2 Study.

C. Flowers, L. Hart, S. Dakhil, 2005 .

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

H. Goldschmidt, P. Sonneveld, K. Anderson, 2005 .

Systemic Mastocytosis Patient Experience from Mast Cell Connect, the First Patient-Reported Registry for Mastocytosis

S. Verstovsek, A. Boral, T. George, 2016 .

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

H. Goldschmidt, P. Sonneveld, S. Lonial, 2004 .

Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study.

R. Fisher, B. Djulbegovic, A. Boral, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

R. Neuwirth, P. Sonneveld, P. Richardson, 2009, British journal of haematology.

Phase I trial and pharmacokinetic study of ISIS 5132 combined with carboplatin and paclitaxel for advanced non-small cell lung cancer

T. Lynch, G. Shapiro, A. Boral, 2000 .

Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study

A. Shields, A. Boral, Hui-Min Lin, 2021, Orphanet Journal of Rare Diseases.

ABC of Bayesian Approaches to Drug Development

Mark Chang, Anthony Boral, A. Boral, 2008, Pharmaceutical Medicine.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of vaccination with lethally irradiated, autologous nonsmall cell lung carcinoma cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor

M. Mihm, G. Dranoff, D. Sugarbaker, 2000 .